Redeye leaves a comment following the announced merger between Magle Group and Amniotics yesterday.
Redeye briefly comments on CLS’ rights issue. We pause our coverage.
Fågelinfluensa i USA kan leda till att pandemiförberedelser intensifieras.
Suominen has today announced a restructuring programme that is expected to generate EUR 1.
Redeye saw a Q1 report showing sales slightly below our estimates, with a total growth of 18% for th...
No deliveries in Q1 compared to one Freemelt ONE expected Opex being kept under control despite inve...
Redeye leaves a comment following the Magle Group’s announced merger with Amniotics yesterday.
We visited Borås Tapetfabrik on Wednesday We assess there is limited technological risk for traditio...
ODI Pharma published on May 30 the company’s Q3-report for 2023/2024, which showed a strong financia...
Syncro Group har publicerat koncernens delårsrapport för det första kvartalet 2024.
Redeye comments on Fluoguide’s Q1 2024 report, following its recent announcement of a collaboration ...
Redeye sees weaker-than-expected US sales, and while this certainly spooked the stock market, we arg...
Windon Energy Group publicerade den 30 maj 2024 bolagets rapport för det första kvartalet 2024.
On Friday, between 10.00-11.00, CEO Gustav Westman and CFO Gustav Norberg presents the company’s qua...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 30 maj 2024 att Bolaget ingått ett utveckli...
CirChem (”CirChem” eller ”Bolaget”) meddelade den 29 maj 2024 att Bolaget beslutat om en riktad nyem...
Företaget ser en fortsatt stark tillväxt framöver och Analysguiden prognostiserar en omsättningsökni...
Japanese sales SEK 29m during first half of 2024, +96% y-o-y Growth driven by largest customer CMP a...
Redeye takes a positive stance on Heliospectra’s capital coverage guarantee, which was announced las...
Redeye comments on the launch of the new eBarrier score, an AI skin barrier assessment tool for rese...
